WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)-- Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now available from Knoll Pharmaceutical Company.
The 8 mg tablets allow easy titration to a higher hydromorphone(Drug information on hydromorphone) dose and are more convenient for patients currently taking two Dilaudid 4 mg tablets per dose, the manufacturer said.
Dilaudid-5 Oral Liquid is designed for patients who have difficulty swallowing solid medications. One teaspoon contains 5 mg of hydromorphone per 5 mL. The liquid is alcohol(Drug information on alcohol)-free, colorless, unflavored, and can be mixed with fruit juice, according to Knoll.
In addition, Knoll is making available a pocket guide "Strategies for Cancer Pain Management," written by Ada Rogers, RN, research associate and clinical coordinator of the Pain Research Group, Memorial Sloan-Kettering Cancer Center.
The guide contains general information on opioid use in cancer pain, as well as specific dosing information on Dilaudid, including a dose conversion chart. Call 201-575-5656 (9 am to 5 pm EST) for free copies.